Janus kinase 2: An epigenetic 'writer' that activates leukemogenic genes

Journal of Molecular Cell Biology

Volumn 2, Issue 5, 2010, Pages 231-233

  He, Jin ^a   Zhang, Yi ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HETEROCHROMATIN SPECIFIC NONHISTONE CHROMOSOMAL PROTEIN HP 1; HETEROCHROMATIN-SPECIFIC NONHISTONE CHROMOSOMAL PROTEIN HP-1; HISTONE; JANUS KINASE 2; NONHISTONE PROTEIN;

ARTICLE; ENZYMOLOGY; GENETIC EPIGENESIS; GENETICS; HETEROCHROMATIN; HUMAN; LEUKEMIA; METABOLISM;

CHROMOSOMAL PROTEINS, NON-HISTONE; EPIGENESIS, GENETIC; HETEROCHROMATIN; HISTONES; HUMANS; JANUS KINASE 2; LEUKEMIA;

EID: 79951476020     PISSN: 16742788     EISSN: 17594685     Source Type: Journal    
DOI: 10.1093/jmcb/mjp054     Document Type: Article

References (11)

1. Bannister, A. J., Zegerman, P., Partridge, J. F., Miska, E. A., Thomas, J. O., Allshire, R. C., and Kouzarides, T. (2001). Selective recognition of methylated lysine 9 on histone H3 by the HP1 (Pubitemid 32225848)
2. Dawson, M. A., Bannister, A. J., Göttgens, B., Foster, S. D., Bartke, T., Green, A. R., and Kouzarides, T. (2009). JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 461, 819-822.
3. Hall, I. M., Shankaranarayana, G. D., Noma, K., Ayoub, N., Cohen, A., and Grewal, S. I. S. (2002). Establishment and maintenance of a heterochromatin domain. Science 297, 2232-2237.
4. Ihle, J. N., and Gilliland, D. G. (2007). JAK2: normal function and role in hematopoietic disorders. Curr. Opin. Genet. Dev. 17, 8-14. (Pubitemid 46109298)
5. McCormack, M. P., and Rabbitts, T. H. (2004). Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 350, 913-922. (Pubitemid 38252539)
6. Neubauer, H., Cumano, A., Muller, M., Wu, H., Huffstadt, U., and Pfeffer, K. (1998). Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93, 397-409. (Pubitemid 28232084)
7. Parganas, E., Wang, D., Stravopodis, D., Topham, D. J., Marine, J.-C., Teglund, S., Vanin, E. F., Bodner, S., Colamonici, O. R., van Deursen, J. M., et al. (1998). Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93, 385-395. (Pubitemid 28232083)
8. Plo, I., Nakatake, M., Malivert, L., de Villartay, J. P., Giraudier, S., Villeval, J. L., Wiesmuller, L., and Vainchenker, W. (2008). JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 112, 1402-1412.
9. Schwaller, J., Parganas, E., Wang, D., Cain, D., Aster, J. C., Williams, I. R., Lee, C. K., Gerthner, R., Kitamura, T., Frantsve, J., et al. (2000). Stat5 is essential for the myelo-and lymphoproliferative disease induced by TEL/JAK2. Mol. Cell 6, 693-704.
10. Shi, S., Calhoun, H. C., Xia, F., Li, J., Le, L., and Li, W. X. (2006). JAK signaling globally counteracts heterochromatin gene silencing. Nat. Genet. 38, 1071-1076. (Pubitemid 44325935)
11. Tefferi, A., Lasho, T. L., and Gilliland, G. (2005). JAK2 mutations in myeloproliferative disorders. N. Engl. J. Med. 353, 1416-1417.